Subscribe to RSS
Download PDF
DOI: 10.4103/ijmpo.ijmpo_160_19
Metastatic Nasopharyngeal Carcinoma: Outcome from Cancer Institute, Chennai
Financial support and sponsorship Nil.
Abstract
Background: Optimal management of metastatic nasopharyngeal carcinoma (NPC) at presentation is debatable. The aim of this study was to investigate the treatment outcome of patients with metastatic NPC treated with concurrent chemoradiation or with radiation alone and to analyze the factors that correlate with the outcome. Methods: This was a retrospective study of patients with metastatic NPC treated in Cancer Institute, Chennai, from 1996 to 2015 with either chemoradiation or only radiation. Factors including age, sex, stage, treatment type, and type of metastasis were correlated with the outcome. Statistical analysis was done using SPSS version 20, and survival was estimated by Kaplan–Meier’s curve. Results: A total of 515 patients with NPC were treated during this period, and among them, 74 patients (14%) had metastasis at the time of presentation. The median follow-up was 14 months; the median progression-free survival and overall survival (OS) were 11 months and 19 months, respectively. About 72% (n = 53) were treated with chemoradiation and the rest 28% (n = 21) were treated with radiation alone. The 3-year OS was better in patients who received chemoradiation (39%) as compared to those who received only radiation (23.8%). Patients with the bone-only site of metastasis had better survival. Among them patients with oligometastatic bone disease (1–3 sites) had a better 3-year OS (51%) as compared to multiple bone metastasis (>3) 15.8%. Conclusion: Chemoradiation can be an option to treat metastatic NPC. Patients with oligometastatic bone disease had better survival.
Publication History
Received: 31 July 2019
Accepted: 19 January 2020
Article published online:
23 May 2021
© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Kataki AC, Simons MJ, Das AK, Sharma K, Mehra NK. Nasopharyngeal carcinoma in the Northeastern states of India. Chin J Cancer 2011; 30: 106-13
- 2 Haleshappa RA, Thanky AH, Kuntegowdanahalli L, Kanakasetty GB, Dasappa L, Jacob L. Epidemiology and outcomes of nasopharyngeal carcinoma: Experience from a regional cancer center in Southern India. South Asian J Cancer 2017; 6: 122-4
- 3 Kunheri B, Agarwal G, Sunil PS, Nair AR, Pushpaja KU. Nasopharyngeal carcinoma: Experience and treatment outcome with radical conformal radiotherapy from a tertiary care center in India. Indian J Cancer 2017; 54: 502-7
- 4 Paiar F, di Cataldo V, Zei G, Pasquetti EM, Cecchini S, Meattini I. et al. Role of chemotherapy in nasopharyngeal carcinoma. Oncol Rev 2012; 6: e1
- 5 Bensouda Y, Kaikani W, Ahbeddou N, Rahhali R, Jabri M, Mrabti H. et al. Treatment for metastatic nasopharyngeal carcinoma. Eur Ann Otorhinolaryngol Head Neck Dis 2011; 128: 79-85
- 6 Tan WL, Tan EH, Lim DW, Ng QS, Tan DS, Jain A. et al. Advances in systemic treatment for nasopharyngeal carcinoma. Chin Clin Oncol 2016; 5: 21
- 7 Jain A, Chia WK, Toh HC. Immunotherapy for nasopharyngeal cancer-a review. Chin Clin Oncol 2016; 5: 22
- 8 Chen WZ, Zhou DL, Luo KS. Long-term observation after radiotherapy for nasopharyngeal carcinoma (NPC). Int J Radiat Oncol Biol Phys 1989; 16: 311-4
- 9 Fandi A, Altun M, Azli N, Armand JP, Cvitkovic E. Nasopharyngeal cancer: Epidemiology, staging, and treatment. Semin Oncol 1994; 21: 382-97
- 10 Frezza G, Barbieri E, Emiliani E, Silvano M, Babini L. Patterns of failure in nasopharyngeal cancer treated with megavoltage irradiation. Radiother Oncol 1986; 5: 287-94
- 11 Ho JH. An epidemiologic and clinical study of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1978; 4: 182-98
- 12 Huang CJ, Leung SW, Lian SL, Wang CJ, Fang FM, Ho YH. Patterns of distant metastases in nasopharyngeal carcinoma. Kaohsiung J Med Sci 1996; 12: 229-34
- 13 Yeh SA, Tang Y, Lui CC, Huang EY. Treatment outcomes of patients with AJCC stage IVC nasopharyngeal carcinoma: Benefits of primary radiotherapy. Jpn J Clin Oncol 2006; 36: 132-6
- 14 Ma SX, Zhou T, Huang Y, Yang YP, Zhan JH, Zhang YX. et al. The efficacy of first-line chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: A systematic review and meta-analysis. Ann Transl Med 2018; 6: 201
- 15 Kua VF, Ismail F, Chee Ee Phua V, Aslan NM. Carboplatin/5-fluorouracil as an alternative to cisplatin/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma. Asian Pac J Cancer Prev 2013; 14: 1121-6
- 16 Bouaouina N, Ouni S, Kanoun SB, Neffeti AB, Kermani W, Abdelkefi M. Metastatic nasopharynx cancer at diagnosis: Clinical and prognostic (study of 51 cases). Pan Afr Med J 2018; 29: 155
- 17 Setton J, Wolden S, Caria N, Lee N. Definitive Treatment of Metastatic Nasopharyngeal Carcinoma: Report of 5 Cases with Review of Literature. Head and Neck 2012; 34: 753-57
- 18 Shen L, Dong J, Li S, Wang Y, Dong A, Shu W. et al. M1 stage subdivision and treatment outcome of patients with bone-only metastasis of nasopharyngeal carcinoma. Oncologist 2015; 20: 291-8